Phase 5 · Metabolic research

Cagrilintide vs Semaglutide

Cagrilintide is an investigational amylin analogue, while semaglutide is an approved GLP-1 medicine with broader and more mature clinical evidence.

The short answer

Different does not automatically mean better.

Cagrilintide is an investigational amylin analogue, while semaglutide is an approved GLP-1 medicine with broader and more mature clinical evidence.

Side ACagrilintide

Side BSemaglutide

Side-by-side

What actually separates them

Compare

Cagrilintide

Semaglutide

Identity

CagrilintideLong-acting analogue of the hormone amylin.

SemaglutideGLP-1 receptor agonist.

Main biological pathway

CagrilintideInvestigated for effects on satiety and food intake through amylin-receptor pathways.

SemaglutideUses GLP-1 signaling to affect appetite, glucose regulation and gastric emptying.

Human evidence

CagrilintidePhase 2 monotherapy evidence and a standalone arm within the large REDEFINE 1 combination study.

SemaglutideExtensive phase 3 evidence across obesity, diabetes and cardiovascular-risk settings.

U.S. regulatory status

CagrilintideCagrilintide alone is not FDA approved as of July 20, 2026.

SemaglutideFDA-approved products have several specific indications.

Best-established context

CagrilintideInvestigational obesity research, including study alone and in combination with semaglutide.

SemaglutideApproved clinical treatment in labeled populations.

Central uncertainty

CagrilintideIts final standalone benefit-risk profile and future regulatory status.

SemaglutideHow individual response and tolerability compare with amylin-based strategies.

Evidence check

Known, unknown, and easy to misread

What is established

REDEFINE 1 included separate cagrilintide and semaglutide arms. In that study, average weight reduction was greater in the semaglutide arm than in the cagrilintide arm.

What is not established

The study’s main focus was the cagrilintide-semaglutide combination versus placebo, so the standalone comparison must be interpreted within that design.

How to read it

These peptides affect different biological pathways. Cagrilintide should not be described as another GLP-1 drug.

Beginner bottom line

Cagrilintide is an investigational amylin analogue, while semaglutide is an approved GLP-1 medicine with broader and more mature clinical evidence.

Quick questions

Frequently asked questions

Is cagrilintide a form of semaglutide?

No. Cagrilintide is an amylin analogue; semaglutide is a GLP-1 receptor agonist.

Is cagrilintide approved for weight management?

Not as a standalone medicine as of July 20, 2026.

Does CagriSema evidence show how cagrilintide works alone?

Not by itself. Combination and standalone study arms must be kept separate.

Check the evidence

Primary and official sources

Want to examine the evidence with the community?

Bring a study, ask a focused question, or compare interpretations in Research Discussions.

Visit Research Discussions